[The concept of innovative drugs has surged, and Haichuang Pharmaceutical has risen by more than 14%] On November 5, the concept of innovative drugs has surged, with Haichuang Pharmaceutical rising by more than 14%, Jinling Pharmaceutical, and Onrica, CSPC Innovation, and Zhongsheng Pharmaceutical following the rise. In the news, Haichuang Pharmaceutical and the American biopharmaceutical company Evommune, Inc. jointly announced that the two parties have reached an exclusive licensing agreement for the oral VAV1 molecular glue degrader HP570 independently developed by Haichuang Pharmaceutical using the targeted protein degradation technology platform. Haichuang Pharmaceutical is also entitled to receive potential development, regulatory registration and commercialization milestone payments of up to approximately US$1.07 billion.